OpenEvidence lands $250M to scale medical AI platform
OpenEvidence has raised $250 million in a Series D funding round, pushing its valuation to $12 billion and cementing its position as the most valuable healthcare AI company globally. The round was co-led by Thrive Capital and DST Global, bringing the company’s total funding to nearly $700 million.
For eeNews Europe readers following AI deployment in regulated, mission-critical environments, OpenEvidence offers a clear case study of how specialized AI architectures and trusted data sources can drive rapid adoption. It also shows how compute-heavy, domain-specific AI is becoming a serious business at scale, not just a research exercise.
A medical search engine at national scale
OpenEvidence describes itself as an AI-powered medical search engine designed to act as a “brain extender” for clinicians. Unlike general-purpose AI models trained on large parts of the internet, the platform is trained exclusively on peer-reviewed medical literature and clinical data. According to the company, more than 40% of physicians in the US now use the system on a daily basis across more than 10,000 hospitals and medical centers.
Usage growth has been sharp. In December alone, OpenEvidence supported around 18 million clinical consultations from verified doctors, compared with about 3 million consultations per month a year earlier. The company says that last year more than 100 million Americans were treated by doctors using the platform.
“If a doctor tried to stay current by reading only the new evidence in the top 10 medical journals and only the most recent changes to their specialty guidelines, it would take nine hours of their day, each day,” said Daniel Nadler, founder and CEO of OpenEvidence. “Without a technology like OpenEvidence, doctors may miss critical new findings or guidelines simply because they lack the time to find them. Doctors want to provide the best care to patients. OpenEvidence is the tool that safely allows them to do that. Our mission is to help doctors save lives and improve patient care.”
Trusted content and multi-agent AI
A key differentiator for OpenEvidence is its early approach to content partnerships. The company has formal AI agreements with organizations such as the New England Journal of Medicine, the American Medical Association, the National Comprehensive Cancer Network and the American College of Cardiology. This allows answers to be generated directly from authoritative sources, with linked citations, boosting trust among clinicians.
The new funding will be used largely for R&D and compute, supporting a multi-agent architecture made up of proprietary, medically specialized AI models. Each model focuses on a specific clinical sub-specialty, with a central “conductor” AI routing questions to the most relevant expert model.
“OpenEvidence is effectively the default operating system of medical knowledge in the United States today,” said Kareem Zaki, partner at Thrive Capital. “We are thrilled to partner with them.”
OpenEvidence is free for doctors and ad-supported, and says it reached $100 million in annual revenue in less than a year after building its commercial team. For the wider AI and semiconductor ecosystem, the company’s growth underlines how vertical AI platforms are driving sustained demand for advanced compute and highly optimized models.
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
